Bradley L. Campbell - 02 Jan 2025 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
President and CEO, Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
02 Jan 2025
Transactions value $
-$651,827
Form type
4
Filing time
06 Jan 2025, 19:04:03 UTC
Previous filing
03 Dec 2024
Next filing
13 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Tax liability -$192K -20.6K -2.33% $9.31 866K 02 Jan 2025 Direct
transaction FOLD Common Stock Award $0 +267K +30.78% $0.00 1.13M 03 Jan 2025 Direct F1
transaction FOLD Common Stock Tax liability -$390K -41.5K -3.66% $9.41 1.09M 03 Jan 2025 Direct
transaction FOLD Common Stock Tax liability -$69.3K -7.37K -0.68% $9.41 1.08M 04 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Award $0 +483K $0.00 483K 03 Jan 2025 Common Stock 483K $9.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2026 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F2 These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.